|Bid||26.46 x 800|
|Ask||27.35 x 1000|
|Day's Range||25.85 - 28.69|
|52 Week Range||15.72 - 146.16|
|Beta (5Y Monthly)||0.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 19, 2022 - Apr 25, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 13, 2012|
|1y Target Est||92.50|
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $30.44, marking a -1.17% move from the previous day.
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $26.43, marking a -1.38% move from the previous day.
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candida